Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
CAMBRIDGE, Mass., Jan. 27, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a leading gene therapy company advancing novel, liver-directed treatments for diverse rare diseases,...
-
CAMBRIDGE, Mass., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a leading gene therapy company advancing novel, liver-directed treatments for diverse rare diseases,...
-
CAMBRIDGE, Mass., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a leading gene therapy company advancing novel, liver-directed treatments for diverse rare diseases,...
-
CAMBRIDGE, Mass., Dec. 4, 2015 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a leading gene therapy company advancing novel, liver-directed treatments for diverse rare diseases,...
-
Dimension Therapeutics Announces Expansion of Internal Research and Process Development Capabilities
CAMBRIDGE, Mass., Nov. 3, 2015 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a leading gene therapy company advancing novel, liver-directed treatments for diverse rare diseases,...
-
CAMBRIDGE, Mass., Oct. 21, 2015 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. ("Dimension" or the "Company"), a leading gene therapy company advancing novel, liver-directed treatments for diverse...